EGFR and non-small cell lung carcinoma: The clinical relevance of these findings is increased by observations, supported by NSCLC clinical trials, suggesting that EGFR-driven ESCCs are unlikely to respond well, or durably, to immune checkpoint inhibitors used in adjuvant and palliative care settings in ESCC, and so require alternate treatment strategies.